Duality Biotherapeutics (FRA:4ZB) Other Long-Term Liabilities: €21.9 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4ZB Duality Biotherapeutics Inc FRA:4ZB
19 GF Score
Price €19.70
! 2 Warning Signs
View Full Analysis

What is Duality Biotherapeutics Other Long-Term Liabilities?

Duality Biotherapeutics FRA:4ZB +6.49% 19 Other Long-Term Liabilities is €21.9 Mil as of Jun. 2026. GuruFocus rates FRA:4ZB with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Duality Biotherapeutics's other long-term liabilities for the quarter that ended in Jun. 2026 was €21.9 Mil.

Duality Biotherapeutics's quarterly other long-term liabilities increased from Jun. 2025 (€47.1 Mil) to Dec. 2025 (€50.0 Mil) but then declined from Dec. 2025 (€50.0 Mil) to Jun. 2026 (€21.9 Mil).

Duality Biotherapeutics's annual other long-term liabilities increased from Dec. 2023 (€7.7 Mil) to Dec. 2024 (€31.5 Mil) and increased from Dec. 2024 (€31.5 Mil) to Dec. 2025 (€50.0 Mil).

Duality Biotherapeutics Other Long-Term Liabilities Related Terms

Duality Biotherapeutics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Duality Biotherapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duality Biotherapeutics Other Long-Term Liabilities Chart

Duality Biotherapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
-0.00 7.68 31.52 50.01

Duality Biotherapeutics Semi-Annual Data
Jun25 Dec25 Jun26
Other Long-Term Liabilities 47.08 50.01 21.85
FRA:4ZB
19GF Score
Duality Biotherapeutics Inc FRA:4ZB
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Duality Biotherapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of €21.9 Mil mean?
Duality Biotherapeutics (FRA:4ZB) has a Other Long-Term Liabilities of €21.9 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Duality Biotherapeutics and its competitors.
Is Duality Biotherapeutics' Other Long-Term Liabilities too high?
Duality Biotherapeutics' current Other Long-Term Liabilities is €21.9 Mil. Overall, Duality Biotherapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Duality Biotherapeutics' Other Long-Term Liabilities compare to VRTX and REGN?
Duality Biotherapeutics' Other Long-Term Liabilities of €21.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Duality Biotherapeutics and its competitors. Duality Biotherapeutics's current Other Long-Term Liabilities is €21.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duality Biotherapeutics stock overvalued right now?
Duality Biotherapeutics (FRA:4ZB) has a current Other Long-Term Liabilities of €21.9 Mil. The current Other Long-Term Liabilities is €21.9 Mil. Duality Biotherapeutics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Duality Biotherapeutics (FRA:4ZB), the current Other Long-Term Liabilities is €21.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Duality Biotherapeutics Business Description

Other Exchanges 09606:Hong Kong
Address No. 868 Yinghua Road, 11th Floor, Building A, Jian Gong Datang International Plaza, Pudong New Area, Shanghai, CHN
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
19GF Score

Get the complete analysis for FRA:4ZB

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.70
Price